Über das Unternehmen
- Firmenname (rechtlich): Bioworkshops
- Registrierungsland: China
- Adresse: No. 5, Dongwang Road,, Suzhou Industrial Park, Suzhou
- Anzahl der Mitarbeiter: 100 - 249
Beschreibung:
A full-service CDMO for antibody products, Bioworkshops offers development and cGMP manufacturing of drug substance and final product, including cell line development, process development, analytical methods, formulation, and process characterization/validation, with 13,000 liters of single-use cell culture capacity (200L to 2000L), three aseptic filling lines for vials, lyophilized products and prefilled syringes/cartridges up to 100,000 units per batch, along with product testing and CTD dossier support.
Geschäftsaktivitäten
Biopharmazeutische Produkte
Lohnhersteller (CMO)Unternehmen in der Frühphase (Start-up)
ATC-Klassifikation (Anatomisch-Therapeutisch-Chemisch)
Lohnhersteller (CMO)Unternehmen in der Frühphase (Start-up)
Original-Wirkstoffe
Lohnhersteller (CMO)Unternehmen in der Frühphase (Start-up)
Hauptprodukte/-dienstleistungen
- Biopharmazeutische Produkte: Trastuzumab emtansine, Trastuzumab deruxtecan, Bedinvetmab, Benralizumab, Bevacizumab, Burosumab, Camrelizumab, Canakinumab, Casirivimab, Cetuximab, Cilgavimab, Daratumumab, Denosumab, Disitamab Vedotin, Dostarlimab, Dulaglutide, Dupilumab, Durvalumab, Eculizumab, Emicizumab, Erenumab, Etesevimab, Evolocumab, Faricimab, Fremanezumab, Frunevetmab, Galcanezumab, Guselkumab, Hyaluronidase Recombinant Human, Imdevimab, Lanadelumab, Lecanemab, Lokivetmab, Mepolizumab, Nirsevimab, Nivolumab, Ocrelizumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Ranibizumab, Ravulizumab, Recombinant Zoster Vaccine, Risankizumab, Rituximab, Romiplostim, Romosozumab, Sarilumab, Sotatercept-csrk, Tezepelumab, Theralizumab, Tixagevimab & Cilgavimab, Tocilizumab, Trastuzumab, Ustekinumab, Adalimumab, Anifrolumab, Atezolizumab, Bamlanivimab, Bebtelovimab
- Biopharmazeutische Dienstleistungen: Cell Line Development, GMP manufacturing for cell culture products
- ATC-Klassifikation (Anatomisch-Therapeutisch-Chemisch): Respiratory Syncytial Virus Vaccine
Unsere Produkte & Dienstleistungen
Sell · Biopharmaceutical Products
Certifications
Proofs
CPHI & PMEC China 2026
06/2026 – 06/2026
CPHI & PMEC China 2026
Bewertungen
(0)
(0)
(0)
(0)
(0)
Kommentare
Filter:
Sortieren nach:
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen